Literature DB >> 21652172

[Azithromycin as an adjuvant therapy in cryptogenic organizing pneumonia].

A P Vaz1, A Morais, N Melo, P Caetano Mota, C Souto Moura, A Amorim.   

Abstract

There are literature data about the immunomodulatory properties of some macrolides in cryptogenic organizing pneumonia (COP) as an alternative to corticosteroids in mild disease or as adjuvant to standard therapy. A sixty-year-old female, with a controlled intrinsic asthma, presented with COP and recurrent respiratory exacerbations despite corticosteroid and immunossupressant therapy. Azithromycin (500mg, on alternate days) as an adjuvant to steroids was then started, with clinical and functional improvement and regression of lung infiltrates. Withdrawal of steroids was possible in one year, without evidence of relapse in the next six months. Azithromycin was maintained (three times per week) with no documentation of adverse side effects. This clinical case reinforces the potential role of macrolides anti-inflammatory properties in COP as corticosteroids adjuvant therapy.
Copyright © 2010 Sociedade Portuguesa de Pneumologia. Published by Elsevier España. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652172     DOI: 10.1016/j.rppneu.2011.03.010

Source DB:  PubMed          Journal:  Rev Port Pneumol        ISSN: 0873-2159


  5 in total

1.  Organizing Pneumonia After Exposure to Sodium Hypochlorite: A Case Report.

Authors:  Inês Santos; Sandra Lucas; Rui Seixas; Ireneia Lino
Journal:  Cureus       Date:  2020-12-11

2.  Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients.

Authors:  A L Vieira; A Vale; N Melo; P Caetano Mota; J M Jesus; R Cunha; S Guimarães; C Souto Moura; A Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.

Authors:  Qun-Li Ding; Dan Lv; Bi-Jiong Wang; Qiao-Li Zhang; Yi-Ming Yu; Shi-Fang Sun; Zhong-Bo Chen; Hong-Ying Ma; Zai-Chun Deng
Journal:  Exp Ther Med       Date:  2015-01-15       Impact factor: 2.447

Review 4.  Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.

Authors:  Sreedhar Amere Subbarao
Journal:  Inflammopharmacology       Date:  2021-03-15       Impact factor: 5.093

5.  Azithromycin for the treatment of eosinophilic nasal polyposis: Clinical and histologic analysis.

Authors:  Isamara Simas de Oliveira; Paulo Fernando Tormin Borges Crosara; Geovanni Dantas Cassali; Diego Carlos Dos Reis; Danilo Santana Rodrigues; Flavio Barbosa Nunes; Roberto Eustáquio Santos Guimarães
Journal:  Allergy Rhinol (Providence)       Date:  2016-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.